Institution
Cubist Pharmaceuticals
Company•Lexington, Massachusetts, United States•
About: Cubist Pharmaceuticals is a company organization based out in Lexington, Massachusetts, United States. It is known for research contribution in the topics: Daptomycin & Vancomycin. The organization has 638 authors who have published 676 publications receiving 35098 citations.
Topics: Daptomycin, Vancomycin, Alvimopan, Lipopeptide, Opioid receptor
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This review discusses recent advances in the understanding of the extracellular matrix and its role in biofilm biology and describes how this contributes significantly to the organization of the community.
1,609 citations
••
Duke University1, Tufts Medical Center2, Drexel University3, Harvard University4, University of Nebraska Medical Center5, Wayne State University6, University of California, San Francisco7, Cubist Pharmaceuticals8, University of California, Los Angeles9, Beaumont Hospital10, East Carolina University11, Dartmouth College12, Veterans Health Administration13, Denver Health Medical Center14, University of Maryland, Baltimore15, University of Cologne16, Lehigh Valley Hospital17, Cleveland Clinic18, Goethe University Frankfurt19, University of Hawaii at Manoa20, Johns Hopkins University21
TL;DR: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
Abstract: Background Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. Methods We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin. The primary efficacy end point was treatment success 42 days after the end of therapy. Results Forty-two days after the end of therapy in the modified intention-to-treat analysis, a successful outcome was documented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who received standard therapy (44.2 percent vs. 41.7 percent; absolute difference, 2.4 percent; 95 percent confidence interval, −10.2 to 15.1 percent). Our results met prespecified criteria for the noninferiority of daptomycin. The success rates were similar in subgroups of patients with complicated bacteremia, right-sided endocarditis, a...
1,318 citations
••
Indiana University1, Pasteur Institute2, Washington University in St. Louis3, University of British Columbia4, Cubist Pharmaceuticals5, University of Turku6, Lahey Hospital & Medical Center7, Harvard University8, University of Medicine and Dentistry of New Jersey9, The Evergreen State College10, Wayne State University11, Tufts University12, Northeastern University13, University of California, Los Angeles14, University of Notre Dame15, University of Birmingham16, MedImmune17, Rockefeller University18, Université catholique de Louvain19, Cardiff University20, Cold Spring Harbor Laboratory21, Robert Koch Institute22, McMaster University23, University of Oklahoma24
TL;DR: To explore how the problem of antibiotic resistance might best be addressed, a group of 30 scientists from academia and industry gathered at the Banbury Conference Centre in Cold Spring Harbor, New York, USA, from 16 to 18 May 2011.
Abstract: The development and spread of antibiotic resistance in bacteria is a universal threat to both humans and animals that is generally not preventable but can nevertheless be controlled, and it must be tackled in the most effective ways possible. To explore how the problem of antibiotic resistance might best be addressed, a group of 30 scientists from academia and industry gathered at the Banbury Conference Centre in Cold Spring Harbor, New York, USA, from 16 to 18 May 2011. From these discussions there emerged a priority list of steps that need to be taken to resolve this global crisis.
929 citations
••
TL;DR: The safety and efficacy of daptomycin were comparable with conventional therapy, and the frequency and distribution of adverse events were similar among both treatment groups.
Abstract: Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics (penicillinase-resistant penicillins [4-12 g iv per day] or vancomycin [1 g iv every 12 h]) in 2 randomized, international trials involving 1092 patients with complicated skin and skin-structure infections. Among 902 clinically evaluable patients, clinical success rates were 83.4% and 84.2% for the daptomycin- and comparator-treated groups, respectively (95% confidence interval, -4.0 to 5.6). Among patients successfully treated with iv daptomycin, 63% required only 4-7 days of therapy, compared with 33% of comparator-treated patients (P<.0001). The frequency and distribution of adverse events were similar among both treatment groups. Overall, the safety and efficacy of daptomycin were comparable with conventional therapy.
657 citations
••
TL;DR: A clear correlation between dissipation of membrane potential and the bactericidal activity of daptomycin is demonstrated and a multistep model for daptomecin's mechanism of action is proposed.
Abstract: The objective of this study was to further elucidate the role of membrane potential in the mechanism of action of daptomycin, a novel lipopeptide antibiotic. Membrane depolarization was measured by both fluorimetric and flow cytometric assays. Adding daptomycin (5 micro g/ml) to Staphylococcus aureus gradually dissipated membrane potential. In both assays, cell viability was reduced by >99% and membrane potential was reduced by >90% within 30 min of adding daptomycin. Cell viability decreased in parallel with changes in membrane potential, demonstrating a temporal correlation between bactericidal activity and membrane depolarization. Decreases in viability and potential also showed a dose-dependent correlation. Depolarization is indicative of ion movement across the cytoplasmic membrane. Fluorescent probes were used to demonstrate Ca(2+)-dependent, daptomycin-triggered potassium release from S. aureus. Potassium release was also correlated with bactericidal activity. This study demonstrates a clear correlation between dissipation of membrane potential and the bactericidal activity of daptomycin. A multistep model for daptomycin's mechanism of action is proposed.
630 citations
Authors
Showing all 638 results
Name | H-index | Papers | Citations |
---|---|---|---|
Sherwood L. Gorbach | 107 | 487 | 44332 |
Mohamed A. Marahiel | 95 | 308 | 31085 |
Julian Davies | 89 | 355 | 35699 |
Paul Schimmel | 89 | 502 | 29788 |
Craig J. Thomas | 66 | 267 | 17653 |
Michael E. Jung | 57 | 574 | 17596 |
Robert D. Arbeit | 56 | 148 | 22210 |
David W. Green | 54 | 261 | 17643 |
Wei Zhang | 47 | 434 | 8481 |
Dirk Schwarzer | 44 | 191 | 7171 |
Andrew Whiting | 43 | 298 | 6400 |
Uwe Linne | 42 | 119 | 5118 |
Henning D. Mootz | 37 | 127 | 7054 |
Rory A. J. Curtis | 36 | 138 | 7587 |
Bruce A. Mueller | 36 | 160 | 4406 |